Calithera Biosciences (CALA)
(Delayed Data from OTC)
$0.02 USD
0.00 (0.00%)
Updated Sep 18, 2024 02:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Calithera Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 25 | 60 | 115 | 157 |
Receivables | NA | 0 | 0 | 2 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 2 | 2 |
Total Current Assets | NA | 27 | 61 | 119 | 160 |
Net Property & Equipment | NA | 0 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 1 |
Total Assets | NA | 29 | 65 | 126 | 169 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 4 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7 | 10 | 16 | 18 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 7 | 14 | 18 | 20 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 8 | 16 | 23 | 26 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 22 | 41 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 511 | 500 | 479 | 428 |
Retained Earnings | NA | -513 | -491 | -376 | -286 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 20 | 49 | 102 | 142 |
Total Liabilities & Shareholder's Equity | NA | 29 | 65 | 126 | 169 |
Total Common Equity | 0 | -2 | 8 | 102 | 142 |
Shares Outstanding | 4.80 | 4.80 | 3.80 | 3.50 | 3.10 |
Book Value Per Share | 0.00 | -0.41 | 2.21 | 29.25 | 45.95 |
Fiscal Year End for Calithera Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | -99,999 |
Receivables | NA | NA | NA | NA | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | NA | NA |
Other Current Assets | NA | NA | NA | NA | NA |
Total Current Assets | NA | NA | NA | NA | NA |
Net Property & Equipment | NA | NA | NA | NA | NA |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | NA | NA | NA |
Intangibles | NA | NA | NA | NA | NA |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | NA | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | NA | NA |
Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | NA | NA | NA |
Other Current Liabilities | NA | NA | NA | NA | NA |
Total Current Liabilities | NA | NA | NA | NA | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | NA | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | NA | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | NA | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | NA | NA |
Capital Surplus | NA | NA | NA | NA | NA |
Retained Earnings | NA | NA | NA | NA | NA |
Other Equity | NA | NA | NA | NA | NA |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | NA | NA | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | NA |
Total Common Equity | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding | 4.80 | 4.80 | 4.80 | 4.80 | 4.80 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |